Abstract:ABSTRACT Riboflavin (vitamin B 2 ) is the precursor of the flavin coenzymes, FAD and FMN, which play a central role in cellular redox metabolism. While humans must obtain riboflavin from dietary sources, certain microbes, including Mycobacterium tuberculosis (Mtb), can biosynthesize riboflavin de novo . Riboflavin precursors have also been implicated in the activation of mucosal-associated invariant T (MAIT) cells which recognize metabolites derived from the riboflavin biosynthesis pathway complexed to the MHC-I-like molecule, MR1. To investigate the biosynthesis and function of riboflavin and its pathway intermediates in mycobacterial metabolism and physiology, we constructed conditional knockdowns (hypomorphs) in riboflavin biosynthesis and utilization genes in Mycobacterium smegmatis (Msm) and Mtb by inducible CRISPR interference. Using this comprehensive panel of hypomorphs, we analyzed the impact of gene silencing on viability, on the transcription of (other) riboflavin pathway genes, on the levels of the pathway proteins, and on riboflavin itself. Our results revealed that (i) despite lacking a canonical transporter, both Msm and Mtb assimilate exogenous riboflavin when supplied at high concentration; (ii) there is functional redundancy in lumazine synthase activity in Msm; (iii) silencing of ribA2 or ribF is profoundly bactericidal in Mtb; and (iv) in Msm, ribA2 silencing results in concomitant knockdown of other pathway genes coupled with RibA2 and riboflavin depletion and is also bactericidal. In addition to their use in genetic validation of potential drug targets for tuberculosis, this collection of hypomorphs provides a useful resource for future studies investigating the role of pathway intermediates in MAIT cell recognition of mycobacteria. IMPORTANCE The pathway for biosynthesis and utilization of riboflavin, precursor of the essential coenzymes, FMN and FAD, is of particular interest in the flavin-rich pathogen, Mycobacterium tuberculosis (Mtb), for two important reasons: (i) the pathway includes potential tuberculosis (TB) drug targets and (ii) intermediates from the riboflavin biosynthesis pathway provide ligands for mucosal-associated invariant T (MAIT) cells, which have been implicated in TB pathogenesis. However, the riboflavin pathway is poorly understood in mycobacteria, which lack canonical mechanisms to transport this vitamin and to regulate flavin coenzyme homeostasis. By conditionally disrupting each step of the pathway and assessing the impact on mycobacterial viability and on the levels of the pathway proteins as well as riboflavin, our work provides genetic validation of the riboflavin pathway as a target for TB drug discovery and offers a resource for further exploring the association between riboflavin biosynthesis, MAIT cell activation, and TB infection and disease.

Riboflavin Biosynthetic and Regulatory Factors As Potential Novel Anti-Infective Drug Targets.

The riboflavin biosynthetic pathway as a novel target for antifungal drugs against species

Inhibitors of riboflavin biosynthetic pathway enzymes as potential antibacterial drugs

The riboflavin biosynthetic pathway as a novel target for antifungal drugs against Candida species

Modulation of riboflavin biosynthesis and utilization in mycobacteria

Biotechnological Strategies of Riboflavin Biosynthesis in Microbes

Thiamin (vitamin B1) biosynthesis and regulation: a rich source of antimicrobial drug targets?

Medicinal benefits, biological, and nanoencapsulation functions of riboflavin with its toxicity profile: A narrative review

New insights into the nutritional genomics of adult-onset riboflavin-responsive diseases

Comparative genomics of NAD(P) biosynthesis and novel antibiotic drug targets

Riboflavin - properties, occurrence and its use in medicine

Metabolic Engineering of Bacillus subtilis for Riboflavin Production: A Review

Riboflavin for women's health and emerging microbiome strategies

Riboflavin Crystals with Extremely High Water Solubility

Therapeutic Target Identification and Inhibitor Screening against Riboflavin Synthase of Colorectal Cancer Associated Fusobacterium nucleatum

Production of vitamin B2 (riboflavin) by Bacillus subtilis

Manipulation of Purine Metabolic Networks for Riboflavin Production in Bacillus subtilis

[Microbial NAD Synthetase and Its Inhibitors--a Review].

Natural biflavonoids as potential therapeutic agents against microbial diseases

Mutations in the riboflavin biosynthesis pathway confer resistance to furazolidone and abolish the synergistic interaction between furazolidone and vancomycin in Escherichia coli.

Effects of deficiency or supplementation of riboflavin on energy metabolism: a systematic review with preclinical studies